Trestle Biotherapeutics was founded with the mission to transform the lives of patients suffering from kidney disease through innovative bioengineered therapies. The core vision is to develop implantable therapeutic tissues that can be surgically delivered to patients with end-stage renal disease, thereby supplementing renal function and reducing dependency on dialysis. This groundbreaking approach aims to significantly improve patient outcomes and extend the time before a kidney transplant becomes necessary.

Notable affiliated people include the founding team, whose expertise and dedication have driven the company's progress. Trestle Biotherapeutics has attracted attention from key investors in the biotech sector, further validating its potential impact. The company’s pioneering work in bioengineered kidneys represents a significant advancement in medical technology, promising to alleviate the burden of dialysis for millions of patients and potentially offering solutions for other types of organ failure in the future.